Stanford University
Showing 451-460 of 624 Results
-
George A. Poultsides, MD, MS
Stanford Department of Surgery Professor
Current Research and Scholarly InterestsClinical trials of experimental diagnostics and therapeutics; outcomes analysis following combined modality treatment of hepatic, pancreatic, and gastrointestinal malignancies.
-
Guillem Pratx
Associate Professor of Radiation Oncology (Radiation Physics)
Current Research and Scholarly InterestsThe Physical Oncology Lab is interested in making a lasting impact on translational cancer research by building novel physical tools and methods.
-
Judith Prochaska
Senior Associate Vice Provost, Clinical Research Governance and Professor of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsDr. Prochaska's clinical trials research focuses on developing and testing evidence-based interventions for tobacco, other substance use, physical activity, and diet. She has led randomized controlled trials of treatments that combine motivational, behavioral, and pharmacologic strategies, including use of telemedicine, therapeutic relational agents, social-media–supported interventions, and tailored programs for socio-demographically diverse and at-risk groups to advance population health.
-
Carla Pugh, MD, PhD
Thomas Krummel Professor
Current Research and Scholarly InterestsThe Technology Enabled Clinical Improvement (T.E.C.I.) Center is a multidisciplinary team of researchers dedicated to the design and implementation of advanced engineering technologies that facilitate data acquisition relating to clinical performance.
-
Lei (Stanley) Qi
Associate Professor of Bioengineering
BioDr. Lei (Stanley) Qi (publishes as Lei S. Qi) is an Associate Professor in the Department of Bioengineering at Stanford University, an Institute Scholar at Sarafan ChEM-H, and a Chan Zuckerberg Biohub Investigator. Trained in physics and mathematics (Tsinghua University) and bioengineering (UC Berkeley), he was a Systems Biology Fellow at UCSF before joining the Stanford faculty in 2014.
Qi is a pioneer in CRISPR technology and genome engineering. His lab created the first nuclease-deactivated Cas9 (dCas9) for targeted gene regulation, establishing CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa). Since then, his group has expanded CRISPR from an editing tool into a platform for programmable control of dynamic and spatial cell state, integrating scalable perturbation, live-cell and super-resolution imaging, and computation-guided design. This work has produced technologies for multiplexed transcriptome regulation, programmable 3D genome organization, spatial RNA logistics control, and real-time visualization of chromatin and transcriptional events in living cells.
A distinctive focus of the Qi lab is closed-loop biology, combining perturbation with high-content measurements to infer mechanisms and iteratively refine control strategies. The lab develops platforms spanning multiplexed transcriptional and epigenetic control, spatial genome–transcriptome organization, and quantitative live-cell imaging of chromatin and transcriptional dynamics. A compact nuclease-dead CRISPR epigenetic editor from this technology lineage has advanced to first-in-human clinical testing for facioscapulohumeral muscular dystrophy (FSHD; NCT06907875), underscoring the translational potential of principle-driven control systems.
Beyond single-cell control, Qi’s lab is building a framework for synthetic cell–cell communication, with particular emphasis on the bidirectional interplay between immune cells and neurons. The lab’s goal is to move beyond describing molecular parts to discovering fundamental control principles in living systems: how regulatory landscapes create stable states and memory, how spatial genome–RNA organization shapes dynamic responses, and how engineered cell–cell interactions can generate emergent multicellular behaviors. By integrating experimental bioengineering with computation and machine learning, the lab aims to identify generalizable rules linking molecular programs to systems-level physiology and disease trajectories and to translate those rules into next-generation therapeutic cells.
